BioSpace News Archive

Inmagene Biopharmaceuticals today announced its partnership with Aditum Bio to create Celexor Bio (Celexor), a new biotech company focused on cell depletion of pathologic cells in autoimmune and inflammatory disorders.

Gurnet Point Capital and Novo Holdings A/S announced the completion of their acquisition of Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats.

Aditum Bio, the biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, today announced the formation of Celexor Bio, a portfolio company created for the development of novel therapies for inflammatory disorders.

The National Kidney Foundation is proud to announce its latest investment through the NKF Innovation Fund, which is aimed at fostering innovation and advancing kidney health.

Prime Therapeutics LLC/Magellan Rx announces Tizgel High as chief compliance officer.

Transcend Therapeutics, a biotechnology company developing rapid-acting treatments for neuropsychiatric diseases, announced receipt of a collaborative grant award with Yale University to support first-of-its-kind preclinical research on methylone – Transcend’s lead compound for the treatment of post-traumatic stress disorder (PTSD).

89bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pegozafermin in patients with nonalcoholic steatohepatitis (NASH).

AIVITA Biomedical, Inc. announced the publication of a case report and literature review by distribution partners commercially deploying AIVITA’s Vaccine Kit, describing collateral benefits in a patient with systemic lupus erythematosus following vaccination using AIVITA’s anti-SARS-CoV-2 vaccine kit.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123).

Akili, Inc. today announced that EndeavorOTC™, the mobile video game treatment clinically proven to improve attention and focus in adults with ADHD, is now available on Google Play™ for popular Android devices, including most Samsung Galaxy and Google Pixel models.